Fan F Zhang
Overview
Explore the profile of Fan F Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Umaretiya P, Naranjo A, Zhang F, Park J, Weiss B, Granger M, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2458531.
PMID: 39951269
Importance: Whether population-based racial and ethnic survival disparities for children with high-risk neuroblastoma persist in the clinical trial setting is unknown. Objective: To investigate racial and ethnic survival disparities among...
2.
Umaretiya P, Naranjo A, Zhang F, Irwin M, Dubois S, Bagatell R, et al.
Pediatr Blood Cancer
. 2024 May;
71(7):e31051.
PMID: 38706187
It is not clear whether trial access disparities exist in the Children's Oncology Group (COG). Here, we leverage a cohort of children with high-risk neuroblastoma (HR-NBL) enrolled on the COG...
3.
Bender H, Irwin M, Hogarty M, Castleberry R, Maris J, Kao P, et al.
J Clin Oncol
. 2023 Apr;
41(17):3149-3159.
PMID: 37098238
Purpose: In 2006, Children's Oncology Group (COG) reclassified subgroups of toddlers diagnosed with neuroblastoma from high-risk to intermediate-risk, when the age cutoff for high-risk assignment was raised from 365 days...
4.
Erbe A, Diccianni M, Mody R, Naranjo A, Zhang F, Birstler J, et al.
J Immunother Cancer
. 2023 Feb;
11(2).
PMID: 36822669
Background: In the Children's Oncology Group ANBL1221 phase 2 trial for patients with first relapse/first declaration of refractory high-risk neuroblastoma, irinotecan and temozolomide (I/T) combined with either temsirolimus (TEMS) or...
5.
Pinto N, Naranjo A, Ding X, Zhang F, Hibbitts E, Kennedy R, et al.
Clin Cancer Res
. 2023 Feb;
29(8):1546-1556.
PMID: 36749880
Purpose: Patients ≥18 months of age with International Neuroblastoma Staging System (INSS) stage 3 unfavorable histology (UH), MYCN-nonamplified (MYCN-NA) tumors have favorable survival rates compared with other high-risk neuroblastoma populations....
6.
Irwin M, Naranjo A, Zhang F, Cohn S, London W, Gastier-Foster J, et al.
J Clin Oncol
. 2021 Jul;
39(29):3229-3241.
PMID: 34319759
Purpose: Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International...
7.
Weiss B, Yanik G, Naranjo A, Zhang F, Fitzgerald W, Shulkin B, et al.
Pediatr Blood Cancer
. 2021 May;
68(10):e29117.
PMID: 34028986
Introduction: I-meta-iodobenzylguanidine ( I-MIBG) is effective in relapsed neuroblastoma. The Children's Oncology Group (COG) conducted a pilot study (NCT01175356) to assess tolerability and feasibility of induction chemotherapy followed by I...
8.
Liu K, Naranjo A, Zhang F, Dubois S, Braunstein S, Voss S, et al.
J Clin Oncol
. 2020 Jun;
38(24):2741-2752.
PMID: 32530765
Purpose: A primary objective of the Children's Oncology Group (COG) ANBL0532 phase III study was to assess the effect of increasing local dose of radiation to a residual primary tumor...
9.
Mody R, Yu A, Naranjo A, Zhang F, London W, Shulkin B, et al.
J Clin Oncol
. 2020 Apr;
38(19):2160-2169.
PMID: 32343642
Purpose: The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with relapsed/refractory neuroblastoma in the randomized Children's Oncology Group ANBL1221 trial. To more accurately...